Literature DB >> 24233105

Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders.

Gail A Edelsohn, James M Schuster, Kim Castelnovo, Lauren Terhorst, Meghna Parthasarathy.   

Abstract

OBJECTIVE: Prescribing patterns of psychotropic medication over a five-year period for Medicaid recipients (adults and children) with codiagnoses of an intellectual disability and a mental disorder were compared with patterns for those with sole mental disorder diagnoses.
METHODS: Each group was identified through paid behavioral health services claims. Four classes of medications (antidepressants, antipsychotics, benzodiazepines, and mood stabilizers) were examined in paid pharmacy claims. Diagnostic categories, rates of psychotropic prescription, and polypharmacy (three or more medications concurrently for 90 days or more) were compared by age group (child or adult).
RESULTS: Adults with mental disorders only (N=793 to 883; the range reflects the five study years) were prescribed antidepressants at a significantly higher rate compared with adults in the codiagnosis group (N=184 to 217). For three of the five study years, antipsychotics were prescribed to the sole-diagnosis group of adults at a significantly higher rate than to those with codiagnoses. Children in the group with codiagnoses (N=108 to 141) were prescribed mood stabilizers at a significantly higher rate than the comparison group (N=638 to 728) in all five study years. Rates of antipsychotics prescribed were not statistically different between the two groups of children. Polypharmacy rates for both adults and children were higher for the codiagnosis group compared with the group with a sole mental disorder, but the difference did not reach statistical significance.
CONCLUSIONS: Psychotropic prescribing patterns in the two groups studied varied by class of medication and age. Although evidence exists for using psychotropics to treat psychopathology and challenging behaviors among individuals with intellectual disabilities, consideration of behavioral intervention alternatives and careful monitoring of psychotropic effectiveness and side effects are recommended.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24233105     DOI: 10.1176/appi.ps.201300029

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  4 in total

Review 1.  Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.

Authors:  Nicole Eady; Ken Courtenay; André Strydom
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

Review 2.  Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis.

Authors:  Cheryl McQuire; Angela Hassiotis; Bronwyn Harrison; Stephen Pilling
Journal:  BMC Psychiatry       Date:  2015-11-26       Impact factor: 3.630

3.  TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities.

Authors:  Sophie Lonchampt; Fabienne Gerber; Jean-Michel Aubry; Jules Desmeules; Marie Besson; Markus Kosel
Journal:  BMJ Open       Date:  2020-11-04       Impact factor: 2.692

4.  Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland.

Authors:  Sophie Lonchampt; Fabienne Gerber; Jean-Michel Aubry; Jules Desmeules; Markus Kosel; Marie Besson
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.